Stocks Health care CING
NASDAQ · Health careCingulate Inc. (CING)
It posted a net loss of $28.8M. In fiscal 2025 capital spending exceeded operating cash flow by $17.4M. At June 30, 2026 it held $28.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Cingulate Inc.
- Net worth
- Cingulate Inc. has a market value (market cap) of $66.3M at the latest share price, and shareholders' equity of $23.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $17.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cingulate Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Cingulate Inc. does
Cingulate Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CING.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$22.4M | -$4.44 | -$17.4M |
| 2024 | n/a | -$16.6M | -$10.86 | -$18.7M |
| 2023 | n/a | -$23.5M | -$332.18 | -$15.3M |
| 2022 | n/a | -$17.7M | -$374.98 | -$16M |
| 2021 | n/a | -$20.7M | -$35.65 | -$11.2M |
| 2021 | n/a | -$7.2M | n/a | -$7.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Cingulate Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026Executive or director change8-KCingulate extended the trial period for the full-time employment of Chief Medical Officer Matthew N. Brams to December 31, 2026.
- August 13, 2026
- August 13, 2026
- July 23, 2026
- July 15, 2026
- July 14, 2026
- July 2, 2026
- June 16, 2026
- June 2, 2026
- May 29, 2026Proxy statement DEF 14A
Insider trades
What the people running Cingulate Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 9, 2026 | Brams MatthewEVP and Chief Medical Officer | Received as pay | 4,526 | - |
| March 9, 2026 | Brams MatthewEVP and Chief Medical Officer | Shares withheld for tax | 1,025 | - |
| March 9, 2026 | Callahan Jennifer L.EVP and CFO | Received as pay | 15,329 | - |
| March 9, 2026 | Callahan Jennifer L.EVP and CFO | Shares withheld for tax | 6,427 | - |
| March 9, 2026 | Patel Nilay DahyabhaiEVP, CLO and CCO | Received as pay | 5,475 | - |
| March 9, 2026 | Patel Nilay DahyabhaiEVP, CLO and CCO | Shares withheld for tax | 2,086 | - |
| March 9, 2026 | Schaffer Shane J.Chief Executive Officer, Director | Received as pay | 6,862 | - |
| March 9, 2026 | Schaffer Shane J.Chief Executive Officer, Director | Shares withheld for tax | 2,959 | - |
Who owns CING
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Falcon Creek Capital Advisor LLC13D, may seek influence with 2 related filers | 28.5% | March 26, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 33 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 570,873 | +261,906 |
| Raymond James Financial Inc | 166,898 | new |
| Chicago Partners Investment Group LLC | 188,429 | +169,679 |
| Kestra Advisory Services, LLC | 151,500 | +11,500 |
| Geode Capital Management, LLC | 144,636 | +43,263 |
| Renaissance Technologies LLC | 127,500 | +95,612 |
| Vanguard Fiduciary Trust Co | 79,160 | +29,086 |
| BlackRock, Inc. | 53,130 | +29,861 |
| BCV Asset Management Inc. | 51,200 | 0 |
| State Street Corp | 47,888 | +20,300 |
| Northern Trust Corp | 35,121 | +12,849 |
| Quantum Private Wealth, LLC | 30,000 | +20,000 |
| Prospera Financial Services Inc | 29,900 | +8,100 |
| Jane Street Group, LLC | 28,878 | -61,989 |
| UBS Group AG | 25,947 | +14,914 |
| Mariner, LLC | 21,281 | +8,351 |
| XTX Topco Ltd | 20,818 | -32,685 |
| Jump Financial, LLC | 14,638 | new |
| PKS Advisory Services, LLC | 11,500 | new |
| Vanguard Global Advisers, LLC | 4,743 | 0 |
Insiders
7 insiders reported holding 259,320 shares in total, about $1.2M at the last price.
| Holder | Shares |
|---|---|
| Werth Peter J.Director | 117,449117,449 held indirectly |
| Hargroves Thomas JeffreyDirector | 97,46897,468 held indirectly |
| Schaffer Shane J.Chief Executive Officer, Director | 14,25110,175 held indirectly |
| Callahan Jennifer L.EVP and CFO | 13,961 |
| Brams MatthewEVP and Chief Medical Officer | 8,157 |
| Silva Raul R.EVP and CSO | 4,645 |
| Patel Nilay DahyabhaiEVP, CLO and CCO | 3,389 |
Questions about CING
What does Cingulate Inc. do?
Cingulate Inc. is a company in the Health care sector, listed on NASDAQ as CING. Its shares trade on NASDAQ under the ticker CING.
What is Cingulate Inc.'s net worth?
Cingulate Inc. has a market value (market cap) of $66.3M at the latest share price, and shareholders' equity of $23.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cingulate Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $28.8M.
When did Cingulate Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from October 2, 2026.
When is Cingulate Inc.'s next earnings report?
Cingulate Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CING with
Follow CING
Get an email when Cingulate Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cingulate Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.